|
|
|
|
|
Last Trade
|
Last Trade:
$2.78
|
Change:
-0.02 (-0.71%)
|
Trade Time:
Aug 10
|
Market Cap:
$64.51M
|
|
|
|
|
|
|
Description of Business
|
|
We are a clinical-stage AI-immunology(TM) platform company using our proprietary
artificial intelligence, or AI, technology, engineering expertise and drug
development know-how to simulate the human immune system and generate predictive
models to identify and develop novel immunotherapies for the treatment of
various cancers, bacterial diseases and viral infections. Drug discovery and
clinical development using historically prevailing techniques is a long, costly
process with a high attrition rate. We believe our proprietary AI-immunology
platforms, trained to translate vast amounts of data into a deep understanding
of biological processes in the human body, can be harnessed to rapidly and cost
effectively design and develop unique immunotherapies, thereby potentially
revolutionizing the process of drug discovery and development.
|
|
|
|